Q3 2024 Organogenesis Holdings Inc Earnings Call Transcript
Key Points
- Organogenesis Holdings Inc (ORGO) delivered sales results above the high end of the guidance range for Q3, indicating strong execution and better-than-expected productivity.
- The company reported a 6% increase in net revenue for the third quarter, with advanced wound care net revenue up 7%.
- Organogenesis Holdings Inc (ORGO) completed enrollment for its second phase three clinical trial ahead of schedule, exceeding the required number of patients.
- The company received a favorable outcome from the interim analysis of its second phase three trial, with the Data Monitoring Committee recommending the trial proceed without modification.
- Organogenesis Holdings Inc (ORGO) secured a $100 million investment from Avista Healthcare Partners, enhancing its balance sheet and financial flexibility for strategic growth initiatives.
- Operating expenses increased by 10% year-over-year, driven by a 12% rise in selling, general, and administrative expenses.
- Operating income for the third quarter decreased by 22% compared to the previous year.
- The company anticipates potential near-term disruption in the market due to expected changes in Medicare coverage for skin substitutes.
- Despite strong revenue growth, the company reported a decrease in adjusted EBITDA margin from 14.7% last year to 12% this year.
- Organogenesis Holdings Inc (ORGO) faces uncertainty regarding the final ruling from Medicare Administrative Contractors, which could impact future revenue.
Welcome, ladies and gentlemen. To the third quarter of fiscal year 2024 earnings conference call for organogenesis holdings inc at this time, all participants have been placed in listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly before we begin. I would like to remind everyone that our remarks today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated including the risks and uncertainties described in the company's filings with the securities and exchange commission including item one, a risk factors of the company's most recent annual report and its subsequently filed quarterly reports.
You are cautioned not to place undue reliance upon any forward-looking statements which speak only as of the date made. Although it may voluntarily do so from time to time the company undertakes no commitment to update or revise the forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
